BTIG raised the firm’s price target on DexCom to $156 from $150 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in MedTech. Large-cap quality stocks should be “best positioned” as increasing geopolitical risks and the fear of “monetary policy stasis” with higher for longer interest rates has investors largely concentrated in large-cap, quality growth names, and these companies are likely best positioned to outperform as investors ride out the macro environment, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom publishes annual sustainability report
- DexCom price target raised to $161 from $148 at Citi
- Court rules DexCom infringed one of three Abbott patents, Bloomberg Law reports
- Early notable gainers among liquid option names on March 25th
- TipRanks’ ‘Perfect 10’ List: Analysts Pound the Table on These Top-Scoring Stocks